Forte Biosciences hosts R&D Day focusing on FB102 autoimmune updates

Forte Biosciences, Inc.

R&D Day held December 3, 2024 highlighting FB102 development in autoimmune indications.
Slide deck (Ex-99.1) and updated corporate presentation (Ex-99.2) furnished with the filing.
No specific clinical data or financial guidance disclosed in the 8-K or exhibits.

item 8.01 item 9.01

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-269949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.